Welcome to our dedicated page for Precipio SEC filings (Ticker: PRPO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the story behind Precipio’s cancer-diagnostic breakthroughs without wading through hundreds of technical pages? Start here. Investors often begin with the Precipio quarterly earnings report 10-Q filing to gauge test-volume growth and reimbursement trends, then scan 8-K updates for FDA milestones or new academic partnerships.
Our platform delivers each SEC document the moment it appears on EDGAR and adds AI-powered summaries that translate complex laboratory terminology into plain English. Whether you need Precipio insider trading Form 4 transactions in real time, a concise view of R&D spending hidden deep in the annual report, or a quick comparison of segment revenues across filings, Stock Titan surfaces it instantly.
Use cases:
- Track executive stock sales with the phrase-matched feed “Precipio executive stock transactions Form 4.”
- Review pipeline progress—our AI highlights every HemeScreen or IV-Cell mention across 10-K and 10-Q filings.
- Assess reimbursement risk via keyword tagging in the proxy statement and risk-factor sections.
The coverage is complete: 10-K annual reports, proxy statements on executive compensation, 8-K material events explained, and every Precipio earnings report filing analysis—all simplified. Understanding Precipio SEC documents with AI means less time decoding regulatory language and more time making decisions.
Precipio, Inc. insider activity: the company’s Chief Operating Officer, Ahmed Zaki Sabet, reported a small open-market purchase of common stock. On 10/01/2025, he acquired 25 shares of Precipio common stock at a price of $19.50 per share, in a transaction coded as a purchase. Following this transaction, he beneficially owns 715 shares of Precipio common stock in direct ownership form. The filing notes that these shares are being purchased pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Precipio, Inc. (PRPO) reported an insider stock purchase by its Chief Operating Officer. On 07/08/2025, the COO acquired 31 shares of common stock in an open-market transaction at $16.3 per share, increasing the directly held position to 690 shares. The filing notes that these shares are being purchased under a pre-established Rule 10b5-1 trading plan adopted by the reporting person, which is designed to provide an affirmative defense against insider trading claims when trading while in possession of material nonpublic information.
Precipio, Inc. (PRPO) reported Q3 2025 results. Net sales were $6,767 thousand, up from $5,209 thousand a year ago, driven by higher diagnostic testing revenue from Medicare and third-party payers. Gross profit rose to $3,005 thousand. Operating loss narrowed to $61 thousand and net loss improved to $79 thousand from $626 thousand.
For the nine months, net sales were $17,350 thousand versus $13,082 thousand, with net loss improving to $889 thousand from $3,925 thousand. Cash at quarter-end was $2,305 thousand, aided by $1,260 thousand of warrant exercise proceeds and $319 thousand provided by operating activities. The company disclosed “substantial doubt” about its ability to continue as a going concern over the next twelve months. As of November 11, 2025, common shares outstanding were 1,752,007.
Precipio, Inc. (PRPO) announced it will host a Q3‑2025 Shareholder Update Call on November 17, 2025 at 5:00 PM ET. The call will include updates on all of the company’s current core businesses.
The company furnished a press release as Exhibit 99.1. The information, including the exhibit, is being furnished and is not deemed filed under the Exchange Act.
Precipio, Inc. (PRPO) reported an insider stock transaction by a director. On October 15, 2025, the director acquired 746 shares of common stock at $17.58 per share. The grant was issued as consideration in lieu of cash compensation for service on the Board of Directors for Q3-25.
Following this transaction, the director beneficially owns 53,572 shares, held directly.
Precipio, Inc. (PRPO) reported an insider transaction by a director. On 10/15/2025, the director acquired 568 shares of common stock in a transaction coded “A,” reflecting a grant in lieu of cash compensation for Board service for Q3‑25. The filing lists a price of $17.58.
Following this grant, the director’s beneficial ownership stands at 15,708 shares, held directly. This is a routine equity compensation event and does not indicate a public offering or company-level capital raise.
Precipio (PRPO): A company director reported acquiring 597 shares of common stock on October 15, 2025 at $17.58 per share. The shares were granted as equity in lieu of cash compensation for service on the Board for Q3-25.
Following the transaction, the reporting person beneficially owns 15,247 shares, held directly.
Precipio (PRPO) director Kathleen D. LaPorte reported acquiring 711 shares of common stock on October 15, 2025 at $17.58 per share. The grant was issued in lieu of cash compensation for service on the Board of Directors for Q3-25.
After this transaction, LaPorte directly owns 6,862 shares of Precipio common stock.
Leviticus Partners LP reports beneficial ownership of 130,000 shares of Precipio, Inc. common stock, representing 8.0% of the class. The filing states the shares are held with sole voting and dispositive power and were acquired and are held in the ordinary course of business, not for the purpose of changing control of the issuer. The filing is signed by Adam M Hutt as Managing Member and dated 09/22/2025. No group affiliations, subsidiaries, or additional arrangements are disclosed.
Kathleen LaPorte, a director of Precipio, Inc. (PRPO), reported the sale of 6,152 shares of the issuer's common stock on 09/08/2025 at a weighted average price of $20.06 per share. After the reported disposals, she beneficially owned 6,151 shares. The shares were originally granted to Ms. LaPorte on 04/15/2024 as consideration in lieu of cash for board service covering Q1 2023 through Q1 2024; that grant was approved by the board under Rule 16b-3 and is exempt from Section 16(b). The Form 4 is signed by Ms. LaPorte on 09/10/2025. The filing notes the shares were sold in multiple transactions at prices ranging from $20.00 to $20.50.
FAQ
What is the current stock price of Precipio (PRPO)?
What is the market cap of Precipio (PRPO)?
